Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Myeong-Ki Hong Added: 7 months ago
ESC 23 — Dr Myeong-Ki Hong (Yonsei University College of Medicine, KR) outlines the late-breaking results from the LODESTAR trial (NCT02579499). LODESTAR (Yonsei University) was a randomized, open-label multicenter trial that aimed to compare the clinical efficacy and safety of atorvastatin vs rosuvastatin for the secondary prevention of coronary artery disease. 4400 coronary artery disease… View more
Author(s): Kausik Ray , , , et al Added: 1 year ago
This Radcliffe medical educational programme has been funded by an arm’s length sponsorship by Novartis Pharmaceuticals UK Limited (“Novartis”). Novartis has had no input in development of the content or involvement in the delivery or execution of the educational programme. In this broadcast, we took a detailed look at how the NHS Long-Term Plan will impact the delivery of lipid-lowering… View more
Author(s): Krishna Prasad Added: 3 years ago
The field of cardiology has seen an unprecedented level of development in recent years both in terms of new therapeutic agents and devices. The field of cardiovascular therapeutics is fast approaching the state of an 'all inclusive area' with the overlap of areas such as diabetes and lipids. With advent of the recent changes to European pharmaceutical regulations, including the clinical trial… View more
Author(s): Morihiro Matsuda , Kanako Yuasa , Toshiharu Kawamoto , et al Added: 3 years ago
Topic: 5. Secondary Prevention of Cardiovascular Disease. Introduction and Objectives Liaison critical pathways (LCPs) for coronary artery disease (CAD) were developed to support collaborative care for CAD patients between cardiologists in emergency hospitals and referring physicians through sharing of medical information, including cardio protective medications and cardiovascular risk… View more
Author(s): J Christoph Geller Added: 3 years ago
Cardiovascular disease is the leading cause of death worldwide. Elevated low-density lipoprotein (LDL) cholesterol levels, hypertension, diabetes and smoking are key modifiable risk factors.1,2 Published practice guidelines3–10 recommend aggressive treatment of individual risk factors and have defined thresholds for the initiation of and goals for treatment (see Table 1). These treatment… View more
Author(s): Martha Gulati Added: 1 year ago
ESC Congress 2022 — In this short and practice-focused review, Dr Martha Gulati, Associate Director of the Barbra Streisand Women Heart Center and Director of CVD Prevention(Cedars-Sinai Medical Center, US) shares some her thoughts on the top 3 hot line trials. Trials covered in detail include: 00:27: TIME:The Treatment in Morning versus Evening 01:57: SECURE:A polypill strategy in secondary… View more
Author(s): Philip A Poole-Wilson Added: 3 years ago
Angina pectoris is a symptom that is usually, in the developed world, caused by obstruction to the coronary arteries by the enlargement of atheromatous lesions; there are other causes. The symptom can limit lifestyle, but more importantly is a repetitive reminder to the patient of the presence of heart disease, causing continual anxiety because of the belief that angina is the portent of early… View more